Edesa Biotech (EDSA) Return on Capital Employed (2015 - 2026)
Edesa Biotech (EDSA) posted Return on Capital Employed of 62.51% for Q4 2025, down 3.42% sequentially from 60.44% in Q3 2025, and up 27528.0% YoY from N/an in Q4 2024.
Edesa Biotech (EDSA) Return on Capital Employed (2015 - 2026) Analysis & Trends
Edesa Biotech has reported Return on Capital Employed for 11 years, with the latest figure at 62.51% in Q4 2025.
- Quarterly Return on Capital Employed rose 27528.0% year-over-year to 62.51% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 62.51% (up 27528.0% YoY) and the FY2025 annual result came in at 104.19%, up 5103.0% from the prior year.
- Return on Capital Employed eased to 62.51% in Q4 2025 per EDSA's latest filing, from 60.44% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 43.1% in Q2 2025 and troughed at 337.79% in Q4 2024.
- A 5-year average of 150.0% and a median of 143.81% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 20127 bps in 2024, then surged 27528 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 223.85% in 2021, then jumped by 33 bps to 150.68% in 2022, then grew by 9 bps to 136.52% in 2023, then plunged by 147 bps to 337.79% in 2024, then surged by 81 bps to 62.51% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 62.51%, 60.44%, and 43.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | -124.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -124.77% |
| Dec 31, 2025 | -62.51% |
| Sep 30, 2025 | -60.44% |
| Jun 30, 2025 | -43.10% |
| Mar 31, 2025 | -68.92% |
| Dec 31, 2024 | -337.79% |
| Sep 30, 2024 | -260.96% |
| Jun 30, 2024 | -240.06% |
| Mar 31, 2024 | -170.14% |
| Dec 31, 2023 | -136.52% |
| Sep 30, 2023 | -125.77% |
| Jun 30, 2023 | -113.76% |
| Mar 31, 2023 | -139.68% |
| Dec 31, 2022 | -150.68% |
| Sep 30, 2022 | -147.94% |
| Jun 30, 2022 | -157.83% |
| Mar 31, 2022 | -163.29% |
| Dec 31, 2021 | -223.85% |
| Sep 30, 2021 | -165.92% |
| Jun 30, 2021 | -103.86% |